To investigate the effect of Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum as an adjuvant to methylprednisolone for non-infectious and idiopathic uveitis
Patients with non-infectious and idiopathic uveitis will receive standard treatment with methylprednisolone, but will be randomized to receive either Beta-1,3/1,6-D-Glucan from mycelium extract of Indonesian Ganoderma lucidum or placebo. Follow up will be performed on week-2, week-4, week-6, month-2, and month-3. Outcomes measured are anterior chamber cells, visual acuity, and serum TNF-alpha levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
20
Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
Placebos
RSCM Kirana
Jakarta Pusat, DKI Jakarta, Indonesia
RECRUITINGChange in anterior chamber inflammatory cells grading
Change in anterior chamber inflammatory cells grading according to SUN nomenclature (0, 0.5+, 1+, 2+, 3+, 4+). 0 is minimum value (better outcome) and +4 is maximum value (worse outcome).
Time frame: Baseline, week-2, week-4, week-6, month-2, month-3
Change of serum TNF-alpha level
Change of serum TNF-alpha level
Time frame: Baseline, week-6, month-3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.